EGFR and vaginal melanoma: In this study, we showed that combinations of selected MET and EGFR inhibitors, crizotinib, foretinib and lapatinib, respectively, act effectively in the two commercially available MM cell lines as well as MM cells isolated from patient's vaginal melanoma.